At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 160 enrolled
Drug / intervention
LY3526318 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Osteoarthritis Pain
In Brief
A Phase 2 clinical trial evaluating LY3526318 and Placebo for Osteoarthritis and Osteo Arthritis Knee. Completed, enrolled 160 participants across 30 sites in 2 countries.
Detailed Summary
The purpose of this study is to test safety and efficacy of study drug LY3526318 in for the treatment of knee pain due to with osteoarthritis (OA). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Osteo Arthritis Knee
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartOct 2021
First PostedOct 2021
Primary CompletionJun 2022
TodayJul 2026
First PostedOct 18, 2021
Enrollment StartOct 12, 2021
Primary CompletionJun 6, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.7 years ago
Interventions
LY3526318drug
Administered orally.
Placebodrug
Administered orally.